Prevention and treatment of atrial fibrillation in oncological patients after thoracic noncardiac surgery
Gorkavyi Ye.O., Golovko V.O. , Ganol O.Yu., Yegorov I.V., Naumenko A.V., Perkonos A.P., Pikulskyi V.V., Sydorenko K.D. , Balakhonov O.I.
Summary. Atrial fibrillation (AF) refers to supraventricular tachyarrhythmia with uncoordinated activation of the atria and their ineffective contraction, which increases the risk of arterial thrombosis and the development of chronic heart failure. The recommendations of the American College of Cardiology / American Heart Association (ACC / AHA) and the American Association for Thoracic Surgery (AATS) and the European Society of Cardiology (ESC) and the European Association of Cardio-Thoracic Surgery (EACTS), propose ways to prevent and treat AF with antiarrhythmic pharmacological and non-pharmacological agents in thoracic surgical patients in the perioperative period. А standardized approach to the prevention and treatment of AF with antiarrhythmic drugs amiodarone and beta blockers in a certain category of oncological patients after thoracic noncardiac surgical operations has been introduced into clinical practice at the National Cancer Institute, in the Department of Anesthesiology and Intensive Care since 2024.
Leave a comment